ARZERRA® (Ofatumumab)

ARZERRA® (Ofatumumab): The FDA on April 17, 2014 approved ARZERRA® in combination with LEUKERAN® (Chlorambucil), for the treatment of previously untreated patients with Chronic Lymphocytic Leukemia (CLL), for whom FLUDARA® (Fludarabine) based therapy is considered inappropriate. ARZERRA® first received accelerated approval in 2009, for the treatment of patients with CLL, refractory to FLUDARA® and CAMPATH® (Alemtuzumab). ARZERRA® injection is given as an intravenous infusion and is a product GlaxoSmithKline.